Tampa General Hospital Pioneers Robotic Endovascular Procedures with Microbot Medical’s LIBERTY System

Tampa General Hospital (TGH) has become the first health system in Florida to adopt the LIBERTY Endovascular Robotic System, developed by Microbot Medical Inc. (Nasdaq: MBOT). This milestone, announced on February 24, 2026, follows the system’s recent FDA 510(k) clearance and signals growing momentum for the innovative technology.

What is the LIBERTY System?

The LIBERTY system is a remotely operated, single-use robotic system specifically designed for peripheral endovascular procedures. It is the only FDA-cleared device of its kind, offering a new level of precision and control for physicians performing these procedures.

The Growing Need for Peripheral Endovascular Procedures

Approximately 2.5 million peripheral endovascular procedures are performed annually in the United States. The LIBERTY system aims to address the increasing demand for minimally invasive treatments for peripheral vascular disease.

Tampa General’s Commitment to Innovation

Tampa General Hospital’s adoption of the LIBERTY system underscores its commitment to providing patients with cutting-edge medical technology. The hospital began a limited market release of the system in late 2025 and plans a full release at the Society of Interventional Radiology conference in April 2026.

Microbot Medical’s Market Position

Microbot Medical’s stock experienced a positive reaction to the news, reflecting investor confidence in the LIBERTY system’s potential. Analysts at B. Riley Securities and Roth Capital have initiated coverage with “Buy” ratings, setting price targets of $5.00 and $5.50 respectively. HC Wainwright & Co. Maintains a “Buy” rating with a $12.00 target.

Key Takeaways

• Tampa General Hospital is the first in Florida to adopt the LIBERTY Endovascular Robotic System.
• The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
• Approximately 2.5 million peripheral endovascular procedures are performed annually in the U.S.
• Microbot Medical plans a full market release of the LIBERTY system in April 2026.